EPISODE · Nov 12, 2025 · 12 MIN
Apogee will have at lest four key trial readouts for its half-life optimized IL-13 program next year, including monotherapy trials and in combination with OX40L and TSLP.
from BiotechTV - News · host BiotechTV
CEO Michael Henderson walks us through what will be a busy year for the company.
Embed this episode
NOW PLAYING
Apogee will have at lest four key trial readouts for its half-life optimized IL-13 program next year, including monotherapy trials and in combination with OX40L and TSLP.
0:00
12:26
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of BiotechTV - News?
This episode is 12 minutes long.
When was this BiotechTV - News episode published?
This episode was published on November 12, 2025.
Can I download this BiotechTV - News episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!